Skip to content

Dianthus Therapeutics

US · DNTH #2155 by market cap Listed 1970
84.55 -0.28 -0.33%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 15 in the most recent period (2026/Q3).
  • Total institutional ownership rose 2.1 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
128.97% +2.10pp
Institutions
347 +15
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund85.15%
Hedge Fund29.53%
VC/PE Fund10.19%
Public Company1.36%
Private Company0.99%
Sovereign Wealth Fund0.75%
Insurance Company0.37%
Government Pension Fund0.36%
Endowment Fund0.26%
Individual/Insider0.15%

Top holders as of 2026-09-30

FMR 15.19% · 8.55M sh
T. Rowe Price Group, Inc. 11.78% · 6.63M sh
BlackRock 7.80% · 4.39M sh
Wellington Management Group 5.74% · 3.23M sh
Fairmount Funds Management LLC 4.51% · 2.54M sh
State Street Global Advisors 4.50% · 2.53M sh
Vanguard Capital Management, LLC 4.31% · 2.43M sh
Avidity Partners Management, L.P. 3.74% · 2.10M sh
Octagon Capital Advisors LP 3.27% · 1.84M sh
TCG Crossover Management, LLC 2.98% · 1.68M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 26 buys · 24 sells

NameRoleStake
Marino Garcia Chief Executive Officer 0.12%
Adam Veness Senior Vice President 0.03%
Simrat Randhawa Executive VP and Head of R&D 0.01%
Alison Lawton Independent Chairperson --
Sujay Kango Independent Director --
Anne McGeorge Independent Director --
Edward Carr Chief Accounting Officer --
Jonathan Violin Independent Director --
Steven Romano Independent Director --
Paula Soteropoulos Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-11 Ryan Savitz Executive VP, CFO, Chief Business Officer & Treasurer Derivative Exercise and Sale -124,042 $8.44–91.59
2026-11-08 Ryan Savitz Executive VP, CFO, Chief Business Officer & Treasurer Intent to Sell (Form 144) -124,042 $86.03
2026-09-16 Edward Carr Chief Accounting Officer Derivative Exercise and Sale -20,000 $17.88–104.39
2026-08-31 Simrat Randhawa Executive VP and Head of R&D Derivative Exercise and Sale -23,124 $17.88–106.74
2026-08-18 Simon Read Independent Director Derivative Exercise and Sale -2,778 $18.36–117.55
2026-08-12 Adam Veness Senior Vice President Derivative Exercise and Retained +15,000 $18.17
2026-08-09 Anne McGeorge Independent Director Derivative Exercise and Sale -7,750 $11.20–111.41
2026-08-09 Simon Read Independent Director Derivative Exercise and Sale -2,777 $18.36–111.77
2026-08-09 Adam Veness Senior Vice President Derivative Exercise and Sale -20,000 $17.88–111.18
2026-08-06 Marino Garcia Chief Executive Officer Derivative Exercise and Sale -166,000 $8.44–110.76
2026-07-08 Ryan Savitz Executive VP, CFO, Chief Business Officer & Treasurer Derivative Exercise and Sale -31,249 $21.77–101.97
2026-06-16 Adam Veness Senior Vice President Derivative Exercise and Sale -30,000 $17.88–81.38
2026-05-31 Simrat Randhawa Executive VP and Head of R&D Derivative Exercise and Sale -26,530 $8.44–91.37
2026-05-20 Alison Lawton Independent Chairperson Other Derivative Acquisition +6,090 $89.63
2026-05-20 Sujay Kango Independent Director Other Derivative Acquisition +6,090 $89.63
2026-05-20 Anne McGeorge Independent Director Other Derivative Acquisition +6,090 $89.63
2026-05-20 Jonathan Violin Independent Director Other Derivative Acquisition +6,090 $89.63
2026-05-20 Steven Romano Independent Director Other Derivative Acquisition +6,090 $89.63
2026-05-20 Paula Soteropoulos Independent Director Other Derivative Acquisition +6,090 $89.63
2026-05-20 Simon Read Independent Director Other Derivative Acquisition +6,090 $89.63

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:59:44 · For reference only, not investment advice and not tailored to your situation.

Dianthus Therapeutics discussion 0 comments

Add a comment